Jefferson Sabatini, MD
Foot and Ankle Surgery · Huntsville, ALNPI 1528357233
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by In2bones USA, LLC at 38.5% of the total. Among foot and ankle surgery clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $285.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- In2bones USA, LLC$22K
- Linvatec Corporation$14K
- Arthrex$10K
- Paragon 28, Inc.$7K
- Stryker$1K
- Smith+Nephew$489
- plus $2K from 23 others
What the payments were for
- Royalty or licence$6,89312%
- Consulting fees$20,00036%
- Speaking & faculty fees$10,00018%
- Travel & lodging$13,60624%
- Food & beverage$5,38610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| In2bones USA, LLC | 21 | $21,531 |
| Linvatec Corporation | 22 | $13,660 |
| Arthrex | 5 | $10,080 |
| Paragon 28, Inc. | 30 | $7,049 |
| Stryker(2 entities) | 31 | $1,446 |
| Smith+Nephew | 27 | $489 |
| Prime Surgical, LLC | 2 | $247 |
| Amgen | 16 | $232 |
| AbbVie(2 entities) | 7 | $169 |
| Novastep Inc. | 1 | $168 |
| Bioventus LLC | 6 | $131 |
| Exactech, Inc. | 1 | $127 |
| Polynovo North America LLC | 4 | $77 |
| Biocomposites Inc | 2 | $73 |
| Kerecis Limited | 3 | $68 |
| KCI USA, Inc. | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Pacira Pharmaceuticals Incorporated | 1 | $27 |
| Abbott | 1 | $26 |
| Solventum Corporation | 1 | $26 |
| Johnson & Johnson | 1 | $23 |
| Organogenesis Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Averitas Pharma Inc. | 1 | $19 |
| Misonix Inc | 1 | $18 |
| Wound Management Technologies, Inc | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $18 |
| Integra Lifesciences Corporation | 1 | $15 |
| Sanara Medtech Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoLink$20,286
- NeoSpan$11,625
- Quantum Total Ankle$7,123
- Portfolio$5,152
- COLINK SFX$3,967
- COLINK PLATING SYSTEM$1,130
- CoLag$497
- Bun-Yo-Matic$395
- Precision MIS Bunion$377
- SMART28$193
- BioBrace 23mm$175
- ORTHOLOC 2 LAPIFUSE$169
- PECAPLASTY$168
- N/A$152
- INFINITY ADAPTIS$147
- Phantom Fibula Nail$142
- VANTAGE$127
- AUGMENT$125
- PARATROOPER$105
- INBONE$102
How this compares
$55,885 in reported general payments places this provider in the 90th percentile of 40 foot and ankle surgery providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DalvanceDalbavancin Hcl | 19 | $60,822 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 156 | $1,056 |
| Ciclopirox | 24 | $762 |
| Gabapentin | 141 | $718 |
| Meloxicam | 139 | $455 |
| Clindamycin Hcl | 22 | $280 |
| Cephalexin | 57 | $269 |
| Ibuprofen | 60 | $233 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 30 | $197 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 42 | $158 |
| Dextrose In WaterDextrose 5 % In Water | 16 | $129 |
| Oxycodone Hcl | 21 | $127 |
| Pregabalin | 11 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieDalvance | $169 | $60,82219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 40 foot and ankle surgery providers in Alabama.
Other foot and ankle surgery in Huntsville
- Matthew DeorioHuntsville$49K
- David KyleHuntsville$9K
- Beatriz Garcia CardonaHuntsville$2K
- Norman WaldropBirmingham$3.6M
- Justin DaigreDecatur$372K
- John KirchnerHoover$84K
- Patricia AnteroTuscaloosa$35K
- Ashish ShahBirmingham$28K
- Alfred RicciMontgomery$25K
- Swapnil SinghBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.